Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584589 | 0.91 | DGAT1 (0.38) | PIK3CAMTORAKT1L3MBTL1ALDH1A1 | |
| SCHEMBL10239398 | 0.87 | PIK3CA (0.35) | PIK3CAMTORAKT1L3MBTL1ALDH1A1 | |
| SCHEMBL7881024 | 0.86 | PIK3CA (0.33) | PIK3CAMTORAKT1L3MBTL1ALDH1A1 | |
| SCHEMBL10239402 | 0.86 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL10239400 | 0.85 | CHEK1 (0.41) | PIK3CAMTORAKT1L3MBTL1ALDH1A1 | |
| SCHEMBL594420 | 0.85 | PIK3CA (0.33) | PIK3CAMTORAKT1DGAT1 | |
| SCHEMBL2680181 | 0.85 | DGAT1 (0.36) | PIK3CAMTORAKT1DGAT1 | |
| SCHEMBL7886269 | 0.85 | PIK3CA (0.33) | PIK3CAMTORAKT1DGAT1 | |
| SCHEMBL7874285 | 0.83 | CHEK1 (0.34) | PIK3CAMTORAKT1 | |
| SCHEMBL6889950 | 0.83 | CHEK1 (0.32) | PIK3CAMTORAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CA 34/4885MTOR 1/4885AKT1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.